Our findings identify EBF1 as novel interaction partner of TET2, confirm IDH mt-mediated hypermethylation to be a recurrent phenomenon in unrelated types of cancer, and have identified tissue- and cancer- specific effectors as key drivers, and potential therapeutic targets. This evidence concerns the gene TET2 and cancer.